Up-and-Coming Drugs for the Treatment of Vitiligo

키워드

참고문헌 (135)

1. Frisoli ML, "Vitiligo : mechanisms of pathogenesis and treatment", Annu Rev Immunol, 38, pp.621~648 (2020)
2. Picardo M, "Vitiligo", Nat Rev Dis Primers, 1, pp.15011~ (2015)
3. Krüger C, "A review of the worldwide prevalence of vitiligo in children", adolescents and adults, 2012, pp.51, 1206~1212
4. Lee H, "Prevalence of vitiligo and associated comorbidities in Korea", Yonsei Med J, 56, pp.719~725 (2015)
5. Ezzedine K, "Psychosocial effects of vitiligo : a systematic literature review", Am J Clin Dermatol, 22, pp.757~774 (2021)
6. Bibeau K, "Mental health and psychosocial quality-of-life burden among patients with vitiligo : findings from the global VALIANT study", JAMA Dermatol, 159, pp.1124~1128 (2023)
7. Sehgal VN, "Vitiligo : compendium of clinico-epidemiological features", Indian J Dermatol Venereol Leprol, 73, pp.149~156 (2007)
8. Seneschal J, "Worldwide expert recommendations for the diagnosis and management of vitiligo : Position statement from the International Vitiligo Task Force-Part 2 : specific treatment recommendations", J Eur Acad Dermatol Venereol, 37, pp.2185~2195 (2023)
9. van Geel N, "Worldwide expert recommendations for the diagnosis and management of vitiligo : Position statement from the International Vitiligo Task Force Part 1 : towards a new management algorithm", J Eur Acad Dermatol Venereol, 37, pp.2173~2184 (2023)
10. Richmond JM, "Innate immune mechanisms in vitiligo : danger from within", Curr Opin Immunol, 25, pp.676~682 (2013)
11. Thulasingam S, "miR-27b*, an oxidative stress-responsive microRNA modulates nuclear factor-kB pathway in RAW 264. 7 cells", Mol Cell Biochem, 352, pp.181~188 (2011)
12. Ahn Y, "ATP-P2X7-induced inflammasome activation contributes to melanocyte death and CD8+ T-cell trafficking to the skin in vitiligo", J Invest Dermatol, 140, pp.1794~1804 (2020)
13. Kim JY, "Impact of high-mobility group box 1 on melanocytic survival and its involvement in the pathogenesis of vitiligo", Br J Dermatol, 176, pp.1558~1568 (2017)
14. Cui T, "Oxidative stress-induced HMGB1 release from melanocytes : a paracrine mechanism underlying the cutaneous inflammation in vitiligo", J Invest Dermatol, 139, pp.2174~2184 (2019)
15. Xie H, "Vitiligo : how do oxidative stress-induced autoantigens trigger autoimmunity?", J Dermatol Sci, 81, pp.3~9 (2016)
16. Tulic MK, "Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo", Nat Commun, 10, pp.2178~ (2019)
17. Harris JE, "A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin", J Invest Dermatol, 132, pp.1869~1876 (2012)
18. Richmond JM, "Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo", J Invest Dermatol, 139, pp.769~778 (2019)
19. Richmond JM, "Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo", Sci Transl Med, 10, pp.eaam7710~ (2018)
20. Boukhedouni N, "Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo", JCI Insight, 5, pp.e133772~ (2020)
21. Dwivedi M, "Regulatory T cells in vitiligo : implications for pathogenesis and therapeutics", Autoimmun Rev, 14, pp.49~56 (2015)
22. Lee EJ, "ISG15-USP18 dysregulation by oxidative stress promotes IFN-γ secretion from CD8+ T cells in vitiligo", J Invest Dermatol, 144, pp.273~283 (2024)
23. Tanemura A, "Understanding of pathomechanisms and clinical practice for vitiligo", Ann Dermatol, 35, pp.333~341 (2023)
24. Villarino AV, "Mechanisms of Jak", STAT signaling in immunity and disease, 2015, pp.194, 21~27
25. Rashighi M, "Interfering with the IFN-γ", CXCL10 pathway to develop new targeted treatments for vitiligo, 2015, pp.3, 343~
26. Platanias LC, "Mechanisms of type-I-and type-II-interferon-mediated signalling", Nat Rev Immunol, 5, pp.375~386 (2005)
27. Chen X, "Oxidative stress-induced IL-15 trans-presentation in keratinocytes contributes to CD8+ T cells activation via JAK-STAT pathway in vitiligo", Free Radic Biol Med, 139, pp.80~91 (2019)
28. Jacquemin C, "Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells : relevance for cutaneous lupus and vitiligo pathogenesis", Br J Dermatol, 177, pp.1367~1375 (2017)
29. Xu Z, "Anatomically distinct fibroblast subsets determine skin autoimmune patterns", Nature, 601, pp.118~124 (2022)
30. Mesa RA, "Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis", IDrugs, 13, pp.394~403 (2010)
31. Vannucchi AM, "Ruxolitinib versus standard therapy for the treatment of polycythemia vera", N Engl J Med, 372, pp.426~435 (2015)
32. Harris JE, "Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata(AA)", J Am Acad Dermatol, 74, pp.370~371 (2016)
33. Rosmarin D, "Ruxolitinib cream for treatment of vitiligo : a randomised, controlled, phase 2 trial", Lancet, 396, pp.110~120 (2020)
34. Rosmarin D, "Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo", N Engl J Med, 387, pp.1445~1455 (2022)
35. Wolkerstorfer A, "519-Efficacy of prolonged ruxolitinib cream treatment for vitiligo among patients with limited or no initial response at 6 months", Br J Dermatol, 190(Supplement_2), pp.ii66~ii68 (2024)
36. Pandya AG, "Addition of narrow-band UVB phototherapy to ruxolitinib cream in patients with vitiligo", J Invest Dermatol, 142, pp.3352~3355 (2022)
37. "A study to evaluate the safety and efficacy of ruxolitinib cream with phototherapy in participants with vitiligo" (2022)[URL]
38. "A study to assess the safety and efficacy of ruxolitinib cream in participants with genital vitiligo" (2023)[URL]
39. Harrington R, "JAK inhibitors in rheumatoid arthritis : an evidence-based review on the emerging clinical data", J Inflamm Res, 13, pp.519~531 (2020)
40. Craiglow BG, "Tofacitinib citrate for the treatment of vitiligo : a pathogenesis-directed therapy", JAMA Dermatol, 151, pp.1110~1112 (2015)
41. Liu LY, "Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure", J Am Acad Dermatol, 77, pp.675~682 (2017)
42. Azzolino V, "Jak inhibitors reverse vitiligo in mice but do not deplete skin resident memory T cells", J Invest Dermatol, 141, pp.182~184 (2021)
43. McKesey J, "A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo", J Am Acad Dermatol, 81, pp.646~648 (2019)
44. "Role of tofacitinib in vitiligo patients (ETV)" (2022)[URL]
45. Zhang J, "Application of baricitinib in dermatology", J Inflamm Res, 15, pp.1935~1941 (2022)
46. Mumford BP, "Repigmentation of vitiligo with oral baricitinib", Australas J Dermatol, 61, pp.374~376 (2020)
47. Dong J, "Baricitinib is effective in treating progressing vitiligo in vivo and in vitro", Dose Response, 20, pp.15593258221105370~ (2022)
48. Li C, "Efficacy and safety of Janus kinase inhibitors for the treatment of atopic dermatitis : a systematic review and meta-analysis", Dermatology, 238, pp.725~735 (2022)
49. "Evaluation of effect and tolerance of the association of baricitinib and phototherapy versus phototherapy in adults with progressive vitiligo" (2021)[URL]
50. Su X, "Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo", J Am Acad Dermatol, 89, pp.1257~1259 (2023)
51. Pan T, "Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib : a case report", J Dermatolog Treat, 34, pp.2200873~ (2023)
52. Ezzedine K, "500-Patient-reported outcomes following 24 weeks of treatment with upadacitinib in adults with non-segmental vitiligo : results from a phase 2, randomized, double-blind, dose-ranging study", Br J Dermatol, 190(Supplement_2), pp.ii64~ii65 (2024)
53. "A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo" (2023)[URL]
54. Ezzedine K, "Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo : a randomized phase 2b clinical trial", J Am Acad Dermatol, 88, pp.395~403 (2023)
55. Roskoski R Jr, "Properties of FDA-approved small molecule protein kinase inhibitors : a 2024 update", Pharmacol Res, 200, pp.107059~ (2024)
56. Dainichi T, "Alopecia areata : what’s new in the diagnosis and treatment with JAK inhibitors?", J Dermatol, 51, pp.196~209 (2024)
57. Cheuk S, "CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin", Immunity, 46, pp.287~300 (2017)
58. Mackay LK, "The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin", Nat Immunol, 14, pp.1294~1301 (2013)
59. Xu H, "PF-06651600, a dual JAK3", TEC family kinase inhibitor, 2019, pp.14, 1235~1242
60. "A 52-week study of ritlecitinib oral capsules in adults and adolescents with nonsegmental vitiligo (active and stable) tranquillo" (2022)[URL]
61. "A study of ATI-50002 topical solution for the treatment of vitiligo" (2018)[URL]
62. Yagi K, "Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib", Australas J Dermatol, 62, pp.433~434 (2021)
63. Murakami K, "Successful management of severe alopecia areata and vitiligo using topical delgocitinib and a 308-nm excimer laser", Eur J Dermatol, 33, pp.428~430 (2023)
64. octan-8-yl)methanone(PF-06700841), "J Med Chem", 2018, 8597~8612
65. "A phase 2b study to evaluate the efficacy and safety profile of PF-06651600 and PF-06700841 in active non-segmental vitiligo subjects" (2018)[URL]
66. Kirby JS, "Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib(INCB054707)in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study", J Am Acad Dermatol, 90, pp.521~529 (2024)
67. "A study to evaluate efficacy and safety of povorcitinib in participants with nonsegmental vitiligo (STOP-V1)" (2023)[URL]
68. "A study to evaluate efficacy and safety of povorcitinib in participants with nonsegmental vitiligo (STOP-V2)" (2023)[URL]
69. "A study to evaluate the efficacy and safety of INCB054707 in participants with vitiligo" (2021)[URL]
70. "Safety and efficacy of ARQ-252 cream 0.3% in subjects with non-segmental facial vitiligo" (2021)[URL]
71. "Assess the efficacy and safety of SHR0302 ointment in adult patients with vitiligo" (2020)[URL]
72. Zhou C, "A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib(SHR0302)in adult patients with moderate-to-severe alopecia areata", J Am Acad Dermatol, 89, pp.911~919 (2023)
73. Cavalié M, "Maintenance therapy of adult vitiligo with 0. 1% tacrolimus ointment : a randomized, double blind, placebo-controlled study", J Invest Dermatol, 135, pp.970~974 (2015)
74. Mosenson JA, "HSP70i is a critical component of the immune response leading to vitiligo", Pigment Cell Melanoma Res, 25, pp.88~98 (2012)
75. Kato H, "Emerging biologic therapies for systemic lupus erythematosus", Curr Opin Rheumatol, 36, pp.169~175 (2024)
76. "Efficacy and tolerance of the association of anifrolumab (300 mg) IV every four weeks and phototherapy versus phototherapy in adults with progressive vitiligo" (2023)[URL]
77. Bertolotti A, "Type I interferon signature in the initiation of the immune response in vitiligo", Pigment Cell Melanoma Res, 27, pp.398~407 (2014)
78. Riding RL, "Type I interferon signaling limits viral vector priming of CD8+ T cells during initiation of vitiligo and melanoma immunotherapy", Pigment Cell Melanoma Res, 34, pp.683~695 (2021)
79. Atwa MA, "Elevated serum level of interleukin-15 in vitiligo patients and its correlation with disease severity but not activity", J Cosmet Dermatol, 20, pp.2640~2644 (2021)
80. Cellier C, "Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease : a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study", Lancet Gastroenterol Hepatol, 4, pp.960~970 (2019)
81. "Amgen. Evaluation of AMG 714 for vitiligo (REVEAL)" (2020)[URL]
82. Spritz RA, "Recent progress in the genetics of generalized vitiligo", J Genet Genomics, 38, pp.271~278 (2011)
83. Tahvildari M, "Low-dose IL-2 therapy in transplantation, autoimmunity, and inflammatory diseases", J Immunol, 203, pp.2749~2755 (2019)
84. Lykhopiy V, ""IL-2 immunotherapy for targeting regulatory T cells in autoimmunity"", Genes Immun, 24, pp.248~262 (2023)
85. "A clinical study of MK-6194 for the treatment of vitiligo (MK-6194-007)" (2023)[URL]
86. Speeckaert R, "Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo", Exp Dermatol, 26, pp.630~634 (2017)
87. Maxwell L, "Abatacept for rheumatoid arthritis", Cochrane Database Syst Rev, 2009, pp.CD007277~ (2009)
88. Dwivedi M, "Decreased regulatory T-cells and CD4+", CD8+ ratio correlate with disease onset and progression in patients with generalized vitiligo, 2013, pp.26, 586~591
89. "Open-label pilot study of abatacept for the treatment of vitiligo" (2015)[URL]
90. Li H, "Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases", Front Pharmacol, 9, pp.1048~ (2018)
91. Ozturk DG, "MITF-MIR211 axis is a novel autophagy amplifier system during cellular stress", Autophagy, 15, pp.375~390 (2019)
92. Hida T, "Elucidation of melanogenesis cascade for identifying pathophysiology and therapeutic approach of pigmentary disorders and melanoma", Int J Mol Sci, 21, pp.6129~ (2020)
93. Sakkas LI, "Phosphodiesterase 4 inhibitors in immune-mediated diseases : mode of action, clinical applications, current and future perspectives", Curr Med Chem, 24, pp.3054~3067 (2017)
94. Khemis A, "Apremilast in combination with narrowband UVB in the treatment of vitiligo : a 52-week monocentric prospective randomized placebo-controlled study", J Invest Dermatol, 140, pp.1533~1537 (2020)
95. Sharma S, "Apremilast add-on benefits over conventional drugs(ABCD)in unstable non-segmental vitiligo : a 12-week single-center randomized controlled trial", Cureus, 15, pp.e37180~ (2023)
96. Kim HJ, "Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI : a randomized split-body pilot study", J Am Acad Dermatol, 85, pp.1657~1660 (2021)
97. Majid I, "Apremilast is effective in controlling the progression of adult vitiligo : a case series", Dermatol Ther, 32, pp.e12923~ (2019)
98. Kim HJ, "Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin : a randomized, split-body, pilot study in skin types IV-VI", Arch Dermatol Res, 315, pp.215~221 (2023)
99. Tam I, "Repigmentation in a patient with vitiligo on crisaborole 2% ointment", JAAD Case Rep, 11, pp.99~101 (2021)
100. Sun X, "Successful treatment of vitiligo with crisaborole ointment : a report of two cases", Br J Dermatol, 188, pp.436~437 (2023)
101. "Study of efficacy, safety and tolerability of crisaborole and PF-07038124 with and without NBUVB in vitiligo" (2022)[URL]
102. Langendonk JG, "Afamelanotide for erythropoietic protoporphyria", N Engl J Med, 373, pp.48~59 (2015)
103. Minder EI, "Pharmacokinetics and pharmacodynamics of afamelanotide and its clinical use in treating dermatologic disorders", Clin Pharmacokinet, 56, pp.815~823 (2017)
104. Fabrikant J, "A review and update on melanocyte stimulating hormone therapy : afamelanotide", J Drugs Dermatol, 12, pp.775~779 (2013)
105. Grimes PE, "The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo", JAMA Dermatol, 149, pp.68~73 (2013)
106. Lim HW, "Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo : a randomized multicenter trial", JAMA Dermatol, 151, pp.42~50 (2015)
107. Toh JJ, "Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians", J Am Acad Dermatol, 82, pp.1517~1519 (2020)
108. Passeron T, "Indications and limitations of afamelanotide for treating vitiligo", JAMA Dermatol, 151, pp.349~350 (2015)
109. Lim HW, "Indications and limitations of afamelanotide for treating vitiligo-reply", JAMA Dermatol, 151, pp.350~ (2015)
110. "A study to assess the changes in pigmentation and safety of afamelanotide in patients with vitiligo on the face" (2022)[URL]
111. "A study to compare the efficacy and safety of SCENESSE and narrow-band ultraviolet (NB-UVB) light versus NB-UVB light alone in patients with vitiligo" (2023)[URL]
112. Galloway GD, "Periocular cutaneous pigmentary changes associated with bimatoprost use", Arch Ophthalmol, 123, pp.1609~1610 (2005)
113. Prota G, "Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys", Pigment Cell Res, 13, pp.147~150 (2000)
114. Nowroozpoor Dailami K, "Efficacy of topical latanoprost in the treatment of eyelid vitiligo : a randomized, double-blind clinical trial study", Dermatol Ther, 33, pp.e13175~ (2020)
115. Neinaa YM, "A comparative study of combined microneedling and narrowband ultraviolet B phototherapy versus their combination with topical latanoprost in the treatment of vitiligo", Dermatol Ther, 34, pp.e14813~ (2021)
116. Silpa-Archa N, "The efficacy of bimatoprost ophthalmic solution combined with NB-UVB phototherapy in non-segmental and segmental vitiligo : a single-blind randomized controlled study", Sci Rep, 13, pp.6438~ (2023)
117. Kanokrungsee S, "Clinical outcomes of topical bimatoprost for nonsegmental facial vitiligo : a preliminary study", J Cosmet Dermatol, 20, pp.812~818 (2021)
118. Nagui NA, "Assessment of prostaglandin F2-alpha(PGF2α)in lesional and nonlesional skin of vitiligo patients", Int J Dermatol, 61, pp.1390~1396 (2022)
119. Bastonini E, "A protective role for autophagy in vitiligo", Cell Death Dis, 12, pp.318~ (2021)
120. Saxton RA, "mTOR signaling in growth, metabolism, and disease", Cell, 168, pp.960~976 (2017)
121. Nie HQ, "Relationship between autophagy of melanocytes in patients with vitiligo and clinical types", Zhonghua Yi Xue Za Zhi, 96, pp.2064~2069 (2016)
122. Lai ZW, "Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications : a single-arm, open-label, phase 1", 2 trial, 2018, pp.391, 1186~1196
123. Chatterjee S, "A quantitative increase in regulatory T cells controls development of vitiligo", J Invest Dermatol, 134, pp.1285~1294 (2014)
124. "Daily topical rapamycin for vitiligo" (2022)[URL]
125. "Evaluating the efficacy and safety of metformin in vitiligo" (2023)[URL]
126. Ursini F, "Metformin and autoimmunity : a"New Deal"of an old drug", Front Immunol, 9, pp.1236~ (2018)
127. Lee S, "P099: An identification of potential therapeutics for vitiligo by mass screening for 1732 medicines in Korean National Health Insurance database", Proceedings of Korean Dermatological Association Meeting Program Book, pp.422~ (2020), Korean Dermatological Association
128. Pearce EL, "Metabolic pathways in immune cell activation and quiescence", Immunity, 38, pp.633~643 (2013)
129. O’Neill LA, "Metabolism of inflammation limited by AMPK and pseudo-starvation", Nature, 493, pp.346~355 (2013)
130. Yin Y, "Normalization of CD4+ T cell metabolism reverses lupus", Sci Transl Med, 7, pp.274~ (2015)
131. Skurkovich S, "Treatment of alopecia areata with anti-interferon-gamma antibodies", J Investig Dermatol Symp Proc, 10, pp.283~284 (2005)
132. Rashighi M, "CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo", Sci Transl Med, 6, pp.223~ (2014)
133. Richmond JM, "CXCR3 depleting antibodies prevent and reverse vitiligo in mice", J Invest Dermatol, 137, pp.982~985 (2017)
134. Lin X, "The possible role of Wnt", β-catenin signalling in vitiligo treatment, 2023, pp.37, 2208~2221
135. Tang L, "Vitamin D protects human melanocytes against oxidative damage by activation of Wnt", β-catenin signaling, 2018, pp.98, 1527~1537

관련 논문AI추천